What is Baxter International's BPS — net sales?

Baxter International (BAX) reported BPS — net sales of -$2M in Q1 2023.

What does BPS — net sales mean?

The total revenue earned from providing contract manufacturing and sterile fill-finish services to external pharmaceutical and biotechnology companies.

How do you interpret BPS — net sales?

An increase indicates higher demand for the company's contract manufacturing services and successful execution of client production contracts. A decrease may signal contract expirations, reduced client demand, or operational challenges in meeting production schedules.

How does BPS — net sales compare across companies?

Comparable to contract development and manufacturing organization (CDMO) revenue streams at peer life sciences and medical technology firms.

Baxter International BAX BPS — Net Sales

Discontinued — last reported Q1 '23

Other product segments

Infusion Therapies & Technologies

$981M-1.3%

Care & Connectivity Solutions

$435M+1.9%

Drug Compounding

$320M+30.1%

Advanced Surgery

$304M+13.4%

Injectables & Anesthesia

$301M-10.1%

Front Line Care

$270M-2.5%

Similar metrics at other companies

BDXBioPharma Systems — Segment Cost of Products and Services Sold as a Percent of Revenues

53.6%+0.4pp

BIIBContract manufacturing revenue — Total Revenue

$237.2M-16.0%

WSTContract-Manufactured Products — Net Sales

$143.2M+6.2%

BBIONet Product Revenue — Revenue

$71.5M—

BDXBioPharma Systems — Segment Operating Income (Loss) as a Percent of Revenues

38.1%-0.8pp

BRKRBsi Biospin — Revenue

$197.5M-5.0%

Other financials

Income statement

See full

Revenue$2.7B+2.9%

Gross profit$891.0M+3.5%

Operating income$66.0M+13.8%

Net income-$15.0M-112%

EPS (diluted)-$0.03-112%

Balance sheet

See full

Cash & equivalents$2.0B-12.1%

Total debt$224.0M-8.9%

Total equity$6.0B-14.7%

Total assets$19.8B-6.8%

Cash flow

See full

Operating cash flow$213.0M+210%

CapEx$128.3M+15.0%

Free cash flow$83.0M-42.1%

Valuation

See full

Market cap$10.27B-50.6%

Enterprise value$8.48B-55.6%

P/S0.9×-1.0×

Profitability

See full

Gross margin30.1%-5.9pp

Operating margin-2.7%—

Net margin-9.7%+62.5pp

FCF margin3%-2.4pp

Returns & leverage

See full

Return on equity-16.7%-76.7pp

Debt / equity0×0.0×

Current ratio1.9×-0.2×

Where this comes from

Reported directly by Baxter International in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Baxter International’s 10-K, filed February 21, 2025, on SEC EDGAR. View the filing →

Ask your AI about Baxter International's bps — net sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Baxter International's BPS — net sales?: Baxter International (BAX) reported BPS — net sales of -$2M in Q1 2023.
What does BPS — net sales mean?: The total revenue earned from providing contract manufacturing and sterile fill-finish services to external pharmaceutical and biotechnology companies.
How do you interpret BPS — net sales?: An increase indicates higher demand for the company's contract manufacturing services and successful execution of client production contracts. A decrease may signal contract expirations, reduced client demand, or operational challenges in meeting production schedules.
How does BPS — net sales compare across companies?: Comparable to contract development and manufacturing organization (CDMO) revenue streams at peer life sciences and medical technology firms.